News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,946 Results
Type
Article (8017)
Company Profile (140)
Press Release (476788)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166756)
Career Advice (305)
Deals (25739)
Drug Delivery (7)
Drug Development (52882)
Employer Resources (14)
FDA (9760)
Job Trends (8575)
News (238208)
Policy (17906)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33158)
ALS (105)
Alzheimer's disease (978)
Antibody-drug conjugate (ADC) (270)
Approvals (10388)
Artificial intelligence (323)
ASCO (159)
Autoimmune disease (206)
Automation (28)
Bankruptcy (263)
Best Places to Work (6959)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (110)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (29)
Breast cancer (513)
Cancer (3674)
Cardiovascular disease (220)
Career advice (245)
Career pathing (1)
CAR-T (174)
CDMO (7)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (47916)
Collaboration (1253)
Commercialization (3)
Compensation (1474)
Complete response letters (34)
COVID-19 (756)
CRISPR (64)
C-suite (757)
Cystic fibrosis (85)
Data (5700)
Denatured (4)
Depression (102)
Dermatology (63)
Diabetes (344)
Diagnostics (4192)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (156)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73731)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87688)
Executive appointments (702)
FDA (12418)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (925)
Gene editing (126)
Generative AI (9)
Gene therapy (320)
GLP-1 (291)
Government (943)
Grass and pollen (2)
Guidances (281)
Healthcare (9325)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (58)
Indications (157)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (258)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (10)
Liver cancer (44)
Longevity (18)
Lung cancer (511)
Lymphoma (253)
Machine learning (27)
Management (3)
Manufacturing (537)
Marketing (8)
MASH (118)
Medical device (8663)
Medtech (8810)
Mergers & acquisitions (14389)
Metabolic disorders (709)
mRNA (59)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (40)
Neuroscience (1833)
NextGen: Class of 2026 (3150)
Non-profit (842)
Obesity (225)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (200)
Parkinson's disease (201)
Partnered (12)
Patents (479)
Patient recruitment (512)
Peanut (31)
People (41255)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15478)
Phase 2 (21393)
Phase 3 (14423)
Pipeline (7414)
Policy (18)
Postmarket research (1570)
Preclinical (6540)
Press Release (34)
Prostate cancer (191)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (576)
Real estate (3019)
Recruiting (6)
Regulatory (14857)
Reports (21)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (156)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (330)
Venture capital (17)
Weight loss (73)
Women's health (81)
Date
Today (16)
Last 7 days (248)
Last 30 days (1441)
Last 365 days (18898)
2026 (12551)
2025 (19251)
2024 (22986)
2023 (26541)
2022 (34588)
2021 (37167)
2020 (33479)
2019 (23276)
2018 (17469)
2017 (18765)
2016 (17917)
2015 (24274)
2014 (21686)
2013 (18141)
2012 (20225)
2011 (20442)
2010 (20333)
Location
Africa (228)
Alabama (74)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17914)
Australia (2100)
California (12040)
Canada (3165)
China (528)
Colorado (486)
Connecticut (413)
Delaware (208)
Europe (24672)
Florida (1802)
Georgia (385)
Hawaii (3)
Idaho (46)
Illinois (705)
India (51)
Indiana (315)
Iowa (15)
Japan (409)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1206)
Massachusetts (7890)
Michigan (308)
Minnesota (563)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2633)
New Mexico (12)
New York (2826)
North Carolina (1290)
North Dakota (4)
Northern California (6037)
Ohio (280)
Oklahoma (14)
Oregon (16)
Pennsylvania (2262)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5003)
Tennessee (120)
Texas (1956)
United States (39074)
Utah (362)
Vermont (1)
Virginia (154)
Washington D.C. (38)
Washington State (932)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
484,946 Results for "imaginab inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
January 23, 2025
·
3 min read
Biotech Beach
ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development
ImaginAb, Inc. announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors.
May 18, 2023
·
2 min read
Drug Development
New analysis of Phase II data at AACR assesses ImaginAb’s investigational CD8 ImmunoPET technology’s ability to predict response in immunotherapy
ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapies announces a poster presentation at AACR 2023 of an independent analysis undertaken by AstraZeneca, on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study.
April 14, 2023
·
2 min read
Biotech Beach
ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio
ImaginAb Inc. is pleased to announce the execution of a new non-exclusive License and Supply Agreement with Leucid Bio, a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell therapies using the Company’s proprietary Lateral CAR Platform.
April 12, 2023
·
3 min read
Business
Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program
Parthenon Therapeutics and ImaginAb Inc. today announced that the companies have entered into a multi-year, non-exclusive license and supply agreement.
November 10, 2022
·
6 min read
Business
Imaging Endpoints (IE) and ImaginAb Inc Expand Partnership - IE to Supply Clinical Doses of CD8 Imaging Agent to BioPharma Companies
Imaging Endpoints (IE) and ImaginAb announced today that after collaborating for nearly a decade they have entered into a license agreement for IE to directly offer clinical doses of ImaginAb’s CD8 investigational ImmunoPET (zirconium Zr 89 crefmirlimab berdoxam) imaging agent for clinical trials as part of Imaging Endpoints’ industry-leading imaging CRO services.
June 3, 2022
·
3 min read
Business
BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer
BriaCell Therapeutics Corp. jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc
August 19, 2021
·
5 min read
Business
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals, announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.
July 23, 2021
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Biotech Beach
ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology
ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement.
January 28, 2021
·
4 min read
1 of 48,495
Next
